CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Docetaxel, Capecitabine and Oxaliplatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00446290
NCT00446290Phase 1Completed
CompareCT.gov

A Phase I Study of Docetaxel, Capecitabine and Oxaliplatin (DXO) in Patients With Advanced Stomach Cancer

Asan Medical Center·interventional·Posted Mar 12, 2007·Updated Jan 18, 2020

In Brief

A Phase 1 clinical trial evaluating Docetaxel, Capecitabine and Oxaliplatin for Stomach Cancer. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Considering synergism between docetaxel (D), capecitabine (X), and oxaliplatin (O) and favourable toxicity profile of oxaliplatin over cisplatin, it is to be expected that combination of docetaxel, capecitabine, and oxaliplatin (DXO) will be more effective than other regimens and feasible in advanced gastric cancer. DXO regimen can be also easily administered on out-patient setting. However, so far, DXO combination has not been tried in advanced gastric cancer. The investigators will determine maximum tolerated dose of DXO regimen in this phase I study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Cancer
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 12, 2007
Enrollment StartMar 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.3 years ago

Interventions

Docetaxel, Capecitabine and Oxaliplatindrug